Ipilimumab, an anti-CTLA4 monoclonal antibody, has received regulatory approval from agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of cancer treatment, including metastatic CRC). Here, CTLA4 is linked to cancer.